Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04688671 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
A Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain, sponsored by Eliem Therapeutics (UK).
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
- 20
- Study locations
NCT04688671: Completed Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain, sponsored by Eliem Therapeutics (UK).
NCT04688671 is a Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain that has completed, run by Eliem Therapeutics (UK). The registered enrollment target is 167 participants, above the 119-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04688671, a Phase 2 study of Diabetic Peripheral Neuropathy and Diabetic Peripheral Neuropathic Pain, has completed, sponsored by Eliem Therapeutics (UK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
Primary Outcome
Change from baseline in the weekly average of the daily pain score as derived from the subject's responses on the Pain Intensity Numerical Rating Scale (PI-NRS) a 10 point scale from 0 being the least (No Pain) to 10 being the most (Worst Possible Pain).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ETX-018810
Study Locations (20)
California
- Neuro-Pain Medical Cneter - Fresno
- Encompass Clinical Research - Spring Valley
- Diabetes Research Center - Tustin
Florida
- Charter Research - Lady Lake
- Cordova Research Institute - Miami
- Coral Research Clinic Corp - Miami
New York
- IMA Clinical Research - New York
- Upstate Clinical Research Associates - Williamsville
Utah
- Alpine Research Organization - Clinton
- Jean Brown Research - Salt Lake City
Alabama
- Delta Clinical Research - Mobile
Arizona
- Arizona Research Center - Phoenix
Connecticut
- Chase Medical Research LLC - Hamden
Georgia
- Better Health Clinical Reseach - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 2 |
What the finished NCT04688671 record still lists
NCT04688671 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 119-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (40% higher).
The record links to 2 conditions, with Diabetic Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04688671 names 20 study sites across 14 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04688671 about?
NCT04688671 is a clinical study titled "Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain". A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy and Safety of ETX 018810 in Subjects with Diabetic Peripheral Neuropathic Pain.
What is the current status of trial NCT04688671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2020-11-09. Estimated completion is 2022-02-18.
What conditions does trial NCT04688671 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT04688671?
The interventions under investigation include: Placebo (DRUG), ETX-018810 (DRUG).
Who is sponsoring clinical trial NCT04688671?
This trial is sponsored by Eliem Therapeutics (UK), which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04688671 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04688671's enrollment target sits among peer trials
167 4th of 17 higher than 14 of 17 other Diabetic Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
COMPLETED · Phase 2
-
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
COMPLETED · Phase 2
-
Walking Function in Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
RECRUITING · NA
-
Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI